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ABSTRACT 
Anorexia nervosa is a highly heritable young-onset psychiatric illness which 
aetiology remains unknown. Estrogen alpha- and beta-receptors, encoded by ESR1 and 
ESR2 genes, are involved in food intake regulation and eating behaviour, and may have a 
potential role in AN. We performed a family-based association study of 17 single-
nucleotide polymorphisms (SNPs) encompassing ESR1 and ESR2 genes in a cohort of 321 
French AN families. We attempted to replicate this finding in a cohort of 41 RAN families 
and in a population-based study of 693 young women. 
Using the transmission disequilibrium test, a significant over-transmission was 
detected between AN and ESR1 rs726281 and rs2295193. These SNPs and another among 
ESR1 were more specifically associated with the restrictive AN subtype (RAN) (rs726281, 
p=0.005, odds ratio [OR]=2.1, 95% Confidence Interval [95%CI]=1.2-3.6; rs3798577, 
p=0.021, OR=1.6, 95%CI=1.1-2.3; and rs2295193, p=0.007, OR=1.7, 95%CI=1.2-2.5). A 
large 8-SNPs haplotype of ESR1 gene was also associated with AN (p<0.0001, OR=3.1, 
95%CI=1.8-5.1). Association of ESR1 SNPs and RAN was driven by paternal over-
transmissions (p<0.0001, OR=3.7, 95%CI=1.9-7.3). Furthermore, we confirmed the 
preferential paternal over-transmission of the ESR1 rs726281 on the independent German 
sample of 41 RAN trios (p=0.025, OR=3, 95%CI=1.1-8.3). Lastly, rs3798577 was 
associated with eating disorders in a population-based sample of 693 women (p<0.01).  
Our findings are strongly in favour of an association between ESR1 polymorphisms 
and anorexia nervosa. Particularly, ESR1 gene confers a high risk of vulnerability to the 
restrictive subtype of anorexia nervosa, and suggests that the estrogen pathway has to be 
further investigated in AN. 
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INTRODUCTION 
Anorexia nervosa (AN, MIM 606788) is an eating disorder characterized by 
weight loss (body mass index < 17.5 kg/m2) or failure to make expected weight gain during 
period of growth, intense fear of gaining weight or becoming fat, body image disturbance 
and amenorrhea (American Psychiatric Association, 1994; Gorwood, et al 2003; Ramoz, et 
al 2007). The prevalence of AN is between 0.3 to 0.6% (Hudson, et al 2007; Ramoz, et al 
2007), with one of the highest mortality rate (about 10% per decade) mainly due to 
cachexia and suicide (Harris and Barraclough, 1994; Hoek, 2006). Furthermore, the 
heritability of AN is high (70%), thus increasing the potential interests of genetic 
approaches (Gorwood, et al 2003; Ramoz, et al 2007). Studies have found evidence of a 
high genetic risk for AN, especially in the restrictive AN subgroup probably because of 
heterogeneity reduction of the phenotype, with, therefore, an increased power to detect an 
association (Grice, et al 2002; Gershon, et al 1984). 
According to the DSM-IV, AN patients are subdivided in two categories: restrictive type 
(RAN), characterizing patients with restricted food intake without binge eating or purging 
episodes, and binge eating/purging type (BPAN), characterizing patients with binge 
eating/purging episodes during anorexia and bulimia phases (American Psychiatric 
Association, 1994). RAN and BPAN patients represent two subtypes with specific clinical 
features, including significant lower BMI in RAN than in BPAN, and an increased 
impulsivity and a higher rate of self-harm and suicide in BPAN than RAN (Eddy, et al 
2002; Foulon, et al 2007; Milos, et al 2004). Hormone concentrations may also help to 
distinguish these two subtypes, since leptin is decreased in RAN compared to BPAN 
(Eddy, et al 2002). 
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Biological pathways of sexual hormones were poorly investigated in AN, although 
the involvement of the estrogenic pathway in AN is supported by several cues. First a 
female predominance is observed in patients with a ratio of 9 women to 1-3 men (Hudson, 
et al 2007; Ramoz, et al 2007). Second, the onset of AN around puberty is correlated to the 
presence of estrogenic peaks. ). Third, recent studies proposed that sex hormones have a 
role in the risk of eating disorders (Culbert KM, et al 2008; Procopio, et al 2007) but this 
observation was not replicated by other authors (Raevuori, et al 2008; Baker, et al 2009). 
Fourth, the anorexic effect of high estrogen levels was found in animal models (Couse and 
Korak, 1999; Wade and Gray, 1979). Moreover, estradiol levels were lower in anorexia 
patients than in controls (Ohwada, et al 2007; Brambilla, et al 2003). Fifth, the ESR1 and 
ESR2 genes, which code for estrogen alpha and beta receptors and are expressed in non-
overlapping brain regions (Osterlund, et al 2000; Osterlund and Hurd, 2001), colocalize 
with corticotrophin releasing factor and modulate its expression (Dagnault and Richard, 
1997; Bao, et al 2005). They participate in the regulation of the hypothalamic pituitary 
adrenal (HPA) axis (Licinio, et al 1996). Thus, the disruption of the HPA axis reported in 
AN might be due to an alteration in the estrogen pathway in patient (Van de Stolpe, et al 
2004). Finally, the involvement of the estrogen alpha receptor in the regulation of food 
intake and eating behaviour was confirmed in mouse models (Musatov, et al 2006; 
Musatov, et al 2007). Two case-control studies of AN with ESR1 and ESR2 genes were 
previously published (Eastwood, et al 2002; Rosenkranz, et al 1998). They reported no 
association of the ESR1 gene with AN, and an inconsistent association of AN with different 
variants within ESR2 gene. 
Thus, our hypothesis is to identify an association between estrogen receptor and 
anorexia nervosa, especially in RAN subgroup, because a diminution of estradiol level was 
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more important in the restrictive compared to the binging-purging subtype (Ohwada, et al 
2007). We more precisely expect to find an association between anorexia nervosa and 
ESR1 gene because ovariectomized rat showed an implication of ESR1 but not of ESR2 
receptor in food intake, body weight and meal size (Santonello, et al 2007). Finally, we 
have been also analysing the role of parental imprinting of this estrogen receptor in 
anorexia nervosa, because ESR1 belongs to the 6q25 region which could be subjected to 
parental imprinting according to database (Nikawa, et al 1996; Morison, et al 2005). 
Furthermore, the absence of ESR1 transcription could be a result of aberrant methylation of 
promoter CpG islands, as shown for example in breast cancers (Wilson, et al 2008). 
Here, we performed the first family-based association study on a large number of AN 
families of French origin looking for an association between ESR1 gene and AN, and we 
took advantage of the narrowing definition of the disorder to show that this association is 
driven by the restrictive subtype of AN. We attempted to replicate the family-based 
association in an independent sample of German families (replication of the TDT 
approach), as well as in an independent population-based sample recruited from the general 
population. 
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MATERIALS AND METHODS 
Subjects and Phenotype 
The study was approved by each national ethics committee. All participants (and if 
underage, their parents) gave written informed consent. 
The first family-based cohort was composed of 321 families of French origin, 
including 210 complete trios, of whom 102 were described previously (Gorwood, et al 
2003). All participants were assessed by clinicians using the face-to-face semi-structured 
Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger, et al 1994). Diagnosis of 
AN were made according to DSM-IV criteria (American Psychiatric Association, 1994), 
and included AN restrictive type (RAN) with no lifetime binge-eating/purging episode 
(N=153 families), and AN binge-eating/purging type (BPAN) with at least one lifetime 
bingeing/purging episode, during anorexia or bulimia phases (N=154 families). Information 
for subtype was incomplete for 14 probands.  
Furthermore, the Eating Disorder Inventory (EDI-2) (Garner, et al 1983) and the 
Eating Attitude Test (EAT-26) (Garner, et al 1982) were used to measure the psychological 
and behavioural dimensions and the broad range of symptoms of AN respectively. 
A second family-based cohort was composed of 41 RAN trios of German origin, the 
probands being assessed with the Composite International Diagnostic Interview (CIDI) 
(Robins, et al 1988). The clinical features of the two family-based cohorts and subgroups 
are described in Table 1. 
A third sample was composed of young women (mean age 20.30 ± 0.05 years) with 
Caucasian origin recruited for a genetic analysis of addictive behaviours, including eating 
disorders (SAGE study) (Le Strat, et al 2009). Eating disorders were assessed using the 
SCOFF scale, a brief and reliable questionnaire developed as a screening test of eating 
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disorders in the general population with a sensitivity of 84.6% and a specificity of 89.6% 
(Hill, et al 2009). Participants were asked the following questions: 1. Do you make yourself 
sick because you feel uncomfortably full? 2. Do you worry you have lost control over how 
much you eat? 3. Have you recently lost more than 6 kg in a 3 month period? 4. Do you 
believe yourself to be fat when others say you are too thin? 5. Would you say that food 
dominates your life? 
Participants were considered as having an eating disorder if they had a SCOFF score 
equal or above 2 (n=126), and were considered as control if they had a SCOFF score lower 
than 2 (n=567). 
 
SNPs and Genotyping 
Genomic DNA from probands and parents was extracted from peripheral blood 
leukocytes. Thirteen SNPs encompassing ESR1 gene and four SNPs within ESR2 gene 
were screened using TaqMan SNP genotyping assays (Applied Biosystems, Les Ullis, 
France). The selection of SNPs is based on tagged SNPs that depict the haplotype blocks 
across the genes, according to available databases (Perlegen and Hapmap) and positive 
associations with diseases. 
Details of SNPs are indicated in Table 2 and Supplementary Table 2 and their 
position within genes are shown on Figure 1 and Supplementary Figure 1 for ESR1 and 
ESR2 genes, respectively. A total of 362 AN patients and 613 parents were genotyped. 
Furthermore, 30 samples were genotyped in duplicate to assess the accuracy of the allelic 
call. SNP rs3798577 was genotyped using SNPlex technology Applied Biosystems, Les 
Ullis, France) for 693 women from the population-based sample (Tobler, et al 2005). 
Versini et al.  NPP-09-0894 
Neuropsychopharmacology 
10 
 
 
Statistical analysis 
Comparisons of clinical features between cohorts and subsets were performed using 
Student’s t-test and Chi-square test. Hardy-Weinberg equilibrium tests, linkage 
disequilibrium D’ values and minor allele frequencies were computed using Haploview 4.1 
software (Barrett, et al 2005). Transmission disequilibrium tests for SNPs and haplotypes 
were carried out with FBAT and PLINK programs (Horvath, et al 2001; Purcell, et al 
2007). Parental origin of the association was calculated using ASPEX 2.5 package (Hinds 
and Risch, 1996). Gene-gene interaction was computed using the gene-based test of the 
PLINK program. The power of sample size for association tests was calculated using the 
Genetic Power Calculator program (http://statgen.iop.kcl.ac.uk/gpc/) (Purcell, et al 2003). 
To take account the linkage disequilibrium between each SNP, we computed correction for 
multiple testing for SNPs using Single Nucleotide Polymorphism Spectral Decomposition 
(SNPSpD) (http://gump.qimr.edu.au/general/daleN/SNPSpD/) (Nyholt, 2004). 
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RESULTS 
Association of ESR1 gene with AN and RAN subset 
We first genotyped 17 SNPs, encompassing ESR1 and ESR2 genes, in a French 
cohort of 321 AN families. All SNPs analyzed in this study were in Hardy-Weinberg 
equilibrium in the patients and parents. No discrepancy was observed in the genotyping of 
30 duplicated samples. Two families were excluded due to Mendelian inheritance errors in 
the paternal transmissions. 
Using transmission disequilibrium tests (TDTs), we found a significant over-
transmission in AN with ESR1 SNPs rs726281 (p=0.024, odds ratio [OR]=1.5, 95% 
confidence interval [95%CI]=1-2) and rs2295193 (p=0.024, OR=1.4, 95%CI=1-1.8), 
(Table 2). We showed that RAN and BPAN subjects differed significantly for several 
clinical variables, particularly regarding the age of onset of anorexia and the minimum 
lifetime BMI (Table 1). Therefore, we performed TDT analyses according to the RAN and 
BPAN subsets. Three ESR1 SNPs were significantly over-transmitted in the RAN subset, 
rs726281 (p=0.005, OR=2.1, 95%CI=1.2-3.6), rs3798577 (p=0.021, OR=1.6, 95%CI=1.1-
2.3) and rs2295193 (p=0.007, OR=1.7, 95%CI=1.2-2.5) (Table 3). In contrast, no SNP was 
associated with the BPAN subgroup (Supplementary Table 1). 
No preferential transmission was found for the ESR2 SNPs in any of the AN 
subgroups (Supplementary Table 2). Furthermore, only one haplotype block encompasses 
the 112 kb of the ESR2 gene that renders unlikely the association between ESR2 gene with 
AN, or with the RAN or BPAN subsets (Supplementary Figure 1). 
No significant epistatic association was found for combinations of ESR1 and ESR2 
SNPs and the AN cohort, neither for the RAN nor for the BPAN subgroups (data not 
shown). 
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Haplotype association in the RAN subset 
Linkage disequilibrium analysis of pairwise SNPs revealed several haplotype blocks 
across the 296 kb of ESR1 gene (Figure 1c). Over-transmissions in the RAN subset were 
found for common haplotypes based on five SNPs (Block 1: rs726281*A-rs3020407*A-
rs17080994*T-rs2982712*T-rs3020371*C, 0.503 frequency, p=0.06), three SNPs (Block 
2: rs2228480*G-rs3798577*T-rs2295193*G, 0.410 frequency, p=0.002), and the eight 
SNPs of the two blocks merged (rs726281*A-rs3020407*A-rs17080994*T-rs2982712*T-
rs3020371*C-rs2228480*G-rs3798577*T-rs2295193*G, 0.230 frequency, p=6.10-6). This 
8-SNPs haplotype presents an odds ratio of 3.1 (95%CI=1.8–5.1) for RAN. 
 
Parental origin of association 
In addition, we analyzed the parental origin of the association with RAN subset. 
Considering the combined TDT of the 13 ESR1 SNPs, we detected a highly significant 
excess of paternal transmission (p=9.10-7) and a significant excess of maternal transmission 
(p=0.0004). More precisely in RAN, a paternal over-transmission of four SNPs (rs726281 
p=0.024, rs2228480 p=0.05, rs3798577 p=0.008 and rs2295193 p=0.004) and a maternal 
over-transmission of rs726281 only (p=0.041) were observed (Table 3). Interestingly, the 
rs726281 over-transmitted by both parents is located in haplotype block 1, while the three 
SNPs solely transmitted in excess by the father constitute block 2 (Figure 1c). Regarding 
the 8-SNPs haplotype in RAN, in comparison to the maternal over-transmission (p=0.02, 
OR=2.1, CI95=1.1–3.8), we found a higher statistical significance for the paternal over-
transmission (p=3.10-5, OR=3.7, 95%CI=1.9–7.3) (Figure 1a). 
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ESR1 association with an independent RAN German cohort 
As a second step, we attempted to replicate the association by genotyping ESR1 SNPs 
in an independent German cohort of 41 RAN trios (Table 4). Although no allele was 
transmitted in excess in the probands of this replication cohort, we found a preferential 
paternal over-transmission of the same SNP which was initially associated in our sample, 
namely the rs726281 (p=0.025), and a trend of significance for rs3798577 (p=0.059), 
conferring a higher risk for RAN in this sample (OR=3.0, 95%CI=1.1-8.3, and OR=2.6, 
95%CI=0.9-7.3, respectively).  
 
ESR1 association with eating disorders in an independent population-based sample 
In a population-based sample of 693 young French Caucasian women (mean age 
20.30 ± 0.05 years), tagged-SNP rs3798577 was found associated with the presence of 
eating disorders (Additive model: p=0.008) (Table 5).  
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DISCUSSION 
In the current study, we found an association between ESR1 gene and AN, mainly 
observed in the restrictive subtype of anorexia nervosa. We showed no association of ESR2 
with AN, nor with RAN or BPAN subgroups. Furthermore, we did not identified ESR1-
ESR2 gene-gene interaction with either AN or restrictive subtype. 
Only two works of AN with ESR1 and ESR2 genes were previously published 
(Rosenkranz, et al 1998; Eastwood, et al 2002). The initial study has screened for mutation 
in ESR2 gene (Rosenkranz, et al 1998) and found different distribution of the variant 
G1082A (rs1256049) in AN compared to BN or to obese/underweight subjects. In the 
second study, no association was reported between AN and 3 markers, or haplotypes, of 
ESR1 gene, but a significant association was reported with the rs1256049 SNP of ESR2 
(Eastwood, et al 2002). Furthermore, an association was also reported with rs4986938 and 
rs928554 (but not with rs1256049) in bulimia nervosa and eating disorders not otherwise 
specified (Nilsson, et al 2004). In the present study, no association was found between 
ESR2 SNPs, which are in linkage disequilibrium (D’>0.9) with rs1256049 according to 
databases, and AN, RAN or BPAN subsets. Noteworthy, our screening of 321 AN families 
using the transmission disequilibrium test was more powerful (1-β = 89%) than the two 
previous case-control studies (1-β = 18% and 63%, respectively) and distinguished RAN 
and BAN.  
We reported a strong association of specific SNPs and haplotypes of the ESR1 gene 
and AN, and RAN subgroup, with a preferential paternal over-transmission. While we 
genotyped a large cohort of families and performed transmission disequilibrium tests that 
reduce the sex and ethnic stratification bias, the probability of a false positive finding in the 
present study cannot be excluded due to the number of tests performed. After a Bonferroni 
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correction taking into account the 13 SNPs within ESR1 gene for the RAN subgroup, we 
found only trends of association for two SNPs, rs726281 pcorrected=0.065 and rs2295193 
pcorrected=0.091, but still observed a strong statistical significance for the 8-SNPs haplotype 
(pcorrected=0.00008). It must be kept in mind that the Bonferroni correction is relevant for 
independent tests. Given that linkage disequilibrium between the 13 SNPs are mainly above 
zero in our sample, this correction is probably over-conservative. In order to assess a more 
appropriate p-value corrected for multiple testing for single SNP association, we carried out 
the Single Nucleotide Polymorphism Spectral Decomposition (SNPSpD) method (Nyholt, 
2004). Significance threshold required is a p<0.0051 (rs726281) and effective number of 
independent SNP is 10 instead of 13. Thus, we found a significant association for rs726281 
pcorrected=0.049 and a trend for rs2295193 pcorrected=0.07. 
The three SNPs of ESR1 associated with RAN in our sample (rs726281, rs3798577 
and rs2295193) are located in introns and 3’ UTR region. To date, they have no known 
functional consequences (Ascenzi, et al 2006). However, the associated haplotype block of 
8 SNPs covers the C terminal E/F region of ESR1 protein, which corresponds to the ligand 
fixation domain of nuclear receptor. So, it is tempting to speculate that the association of 
these SNPs with RAN could suggest changes of ligand fixation in RAN patients. 
We also attempted to replicate our results in an independent German cohort of 41 
RAN trios, but failed to confirm significant associations between ESR1 SNPs and RAN. 
Surprisingly, participants in the German RAN cohort showed a significant higher mean of 
minimal lifetime BMI compared to the French RAN cohort, while they were significantly 
younger and had shorter disease duration. As up to half of the restrictive AN patients cross-
over to binge eating/purging subtype in a 7 years follow-up study (Eddy, et al 2008), this 
difference may explain the absence of replication in the German sample, since, in the latter, 
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young RAN patients could still switch to the BPAN phenotype. While this difference 
between the two cohorts decreases any chances of replication, we were able to observe the 
excess of paternal transmission of the main SNP associated with anorexia nervosa in the 
first sample. Due to a small sample size, the RAN German cohort provided a reduce power 
(power=33%) compared to the RAN French cohort (power=59%) that can explain the low 
significance of association. 
Finally, we tested a tagged-SNP of the ESR1 gene in a large population based sample, 
and found an association with eating disorders, as defined by a SCOFF score equal or 
above 2. However, it should be noted that the SCOFF scale is a screening tool for eating 
disorders rather that a diagnostic instrument for AN, and therefore no direct comparison 
should be made between the two first clinical samples and this population based sample. At 
most, this epidemiological sample gives indirect evidence for replication, which is usually 
regarded as needed for genetic association studies in complex disorders. 
There are several limitations of this study. Firstly, the instruments assessing the eating 
disorders are different in the three cohorts. French and German trios families were assessed 
with semi-structured interview, respectively, DIGS and CIDI, while the self-evaluation 
SCOFF scale was used to screen epidemiological eating disorders in a large woman 
population sample. Secondly, the sample size of the German trios is small with a shorter 
disease evolution period, although a cohort with a larger sample size and a disease duration 
equivalent to the French cohort is recommended to replicate our results. Thirdly, the three 
SNPs of ESR1 (rs726281, rs3798577 and rs2295193), associated with RAN, have no 
known functional consequences up to now and are located in non-coding regions. These 
SNPs required a functional analysis regarding their potential effects of associated alleles in 
ESR1 receptor proprieties. 
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Although there is a lack of report on the genetic aspects of hormonal status as a risk 
factor for anorexia nervosa, recent investigations suggest that some hormonal environment 
might be associated with eating disorders (Procopio and Marriott, 2007; Young, 1991). 
Observations between same-sex and opposite-sex twins allowed to find a high AN 
prevalence in adult life in female compares to male, suggesting an influence of intrauterine 
exposure level to sex hormone (Procopio and Marriott, 2007). Interestingly, significant 
deficiency of serum levels for estradiol, the ligand of estrogen receptor, has been described 
in AN patients compared to controls, and a lower concentration in restrictive subtype rather 
than the binge eating/purging subtype has been reported (Ohwada, et al 2007). It is 
tempting to speculate that the association between ESR1 gene and RAN may lead to 
specific biological effects, such as a modified expression and/or an altered function of the 
estrogen receptor alpha. Furthermore, the paternal transmission of the association that we 
observed also supports a genetic imprinting, which might be influenced by sex hormones. 
Also, it is important to consider DNA methylation in psychiatric disorder because it could 
help to the understanding of mechanism of the pathology and could constitute potential 
therapeutic targets. Acute administration of a selective ER alpha agonist leads to 
ovariectomized rats that showed a decrease in daily food intake and body weight (Santollo, 
et al 2007). Furthermore, in female mice, agonists of ER receptors produce different effects 
on social learning of food preferences (Clipperton, et al 2008). Then, ER alpha antagonist 
treatment failed to reduce food intake decrease in chemically ovariectomized rats (Santollo 
and Eckel, 2009). Finally, in female rat, the level of ESR1 protein expression and estrogen 
sensitivity are modulated by oxytocin (Perry, et al 2009). Thus, it is difficult up to now to 
suggest a pharmacological treatment for AN. Further functional studies are needed to 
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decipher the biological effect of the association identified in our study which may influence 
the number or affinity of ESR1 receptor in restrictive AN patients. 
Our study suggests evidences that common variants in ESR1 gene are associated to 
eating disorders, and more specifically restrictive anorexia nervosa, highlighting the 
possible involvement of estrogenic hormonal pathway in anorexia nervosa that might open 
novel avenues of neuroendocrinopharmacological approaches in this neuropsychiatric 
disorder.
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Figure legends 
Figure 1: ESR1 SNPs, mapping and association with restrictive anorexia nervosa 
(A) Association between restrictive anorexia nervosa and SNPs (filled symbol) or 
haplotypes (open symbol) for combined parental (black triangle), maternal (red circle) and 
paternal (blue square) transmissions. The strongest association is observed for the 8-SNPs 
haplotype (p = 6.10-6). (B) Genomic organization of ESR1 gene (bars correspond to exons 
and arrowhead indicates the orientation of transcription) and position of the 13 
encompassing SNPs (interrupted bars) at scale. (C) Pairwise linkage disequilibrium of 
SNPs. Haplotype blocks 1 and 2 are indicated. The haplotype of 8-SNPs is boxed. 
 
Supplementary Figure 1: Mapping of the ESR2 gene and SNPs and linkage 
disequilibrium 
(A) Genomic organization of ESR2 gene (bars correspond to exons and arrowhead indicates 
the orientation of transcription) and position of the 4 encompassing SNPs (interrupted bars) 
at scale. The two alternative first exons are indicated by a and b. (B) Pairwise linkage 
disequilibrium of SNPs. Note that only one haplotype block encompasses ESR2 gene. 
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Tables 
Table 1: Demographic and clinical data for the French and German family-based cohorts and the French RAN and BPAN subgroups 
Population  French  German 
Disorder AN RAN BPAN RAN 
Families number (N) 321 153 154 41 
Female (%) 97 97 97 95 
Age (years) 22.3 ± 7.4 19.4 ± 6.5 25.2 ± 7.2a 16.0 ± 1.9b 
Age of onset of anorexia (years) 16.2 ± 4.5 15.6 ± 4.4 16.8 ± 4.4a 14.6 ± 1.2  
Duration of anorexia (years) 6.1 ± 6.0 3.9 ± 4.8 8.3 ± 6.2a 1.5 ± 1.3b 
BMI minimum (kg/m2) 13.6 ± 2.2 12.9 ± 1.7 14.4 ± 2.2a 13.5 ± 0.2b 
Major depressive episode (%) 68 68 69 n.a. 
Suicide attempt (%) 28 9 47a n.a. 
Alcohol and drug abuse/dependence (%) 6 2 11a n.a. 
Versini et al.  NPP-09-0894 
Neuropsychopharmacology 
31 
 
EATc Dieting 16.4 ± 10.6 13.4 ± 10.2 19.5 ± 10.3a n.a. 
EAT Bulimia 7.6 ± 6.0 4.6 ± 4.3 10.6 ± 5.8a n.a. 
EAT Oral control 7.4 ± 5.3 7.7 ±5.2 7.2  ± 5.3 n.a. 
 
Data are indicated as N, % or mean ± standard deviation. aSignificant difference between RAN and BPAN from the French cohort. bSignificant 
difference between French RAN subset and German RAN cohort. cEating Attitude Test. Significant difference indicates a p value inferior at 0.05 
in one-way analysis of variance or t-test. Not available, n.a. 
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Table 2: Transmission disequilibrium test of ESR1 SNPs with AN in the French family-based cohort 
    TDT 
SNP# Markers Position MAFa OTb T:Uc p OR [CI95]d 
1 rs488133 152167137 T (0.39) C 102:102 1 1 [0.8-1.3] 
2 rs11155819 152241052 C (0.31) C 105:100 0.727 1.1 [0.8-1.4]
3 rs12199722 152276593 G (0.32) G 99:88 0.421 1.1 [0.8-1.5]
4 rs1884051 152324972 G (0.3) A 81:71 0.417 1.1 [0.8-1.6]
5 rs726281 152344271 G (0.26) A 85:58 0.024e 1.5 [1.0-2.0]
6 rs3020407 152348954 G (0.29) A 95:76 0.146 1.3 [0.9-1.7]
7 rs17081994 152358440 C (0.09) T 36:23 0.091 1.6 [0.9-2.6]
8 rs2982712 152399872 C (0.39) T 106:95 0.438 1.1 [0.8-1.5]
9 rs3020371 152425513 T (0.31) C 93:87 0.655 1.1 [0.8-1.4]
10 rs2228480 152461788 A (0.17) G 55:50 0.626 1.1 [0.8-1.6]
11 rs3798577 152462823 C (0.46) T 116:91 0.082 1.3 [1.0-1.7]
12 rs2295193 152494787 G (0.47) G 117:85 0.024 1.4 [1.0-1.8]
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13 rs2252837 152510513 T (0.35) C 106:87 0.171 1.2 [0.9-1.6]
aMAF: Minor allele and its frequency in the parentheses. bOT: Over-transmitted allele. cT:U: Transmitted versus untransmitted allele. dOR [CI95]: 
odds ratio and the 95% confidence interval. eSignificant p values are indicated in bold. 
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Table 3: Transmission disequilibrium test of ESR1 SNPs with restrictive AN subset of French family-based cohort 
   TDT Maternal TDT Paternal TDT 
SNP# Markers  OTa T:Ub p OR [CI95]c p OR [CI95] p OR [CI95] 
1 rs488133  C 56:51 0.629 1.1 [0.8-1.6] 0.758 .9 [0.5-1.7] 0.237 1.5 [0.8-2.9] 
2 rs11155819  C 51:49 0.841 1 [0.7-1.5] 0.866 1.1 [0.5-2.1] 0.873 1.1 [0.6-2.0] 
3 rs12199722  G 53:40 0.178 1.3 [0.9-2.0] 0.631 1.2 [0.6-2.2] 0.114 1.7 [0.9-3.2] 
4 rs1884051  A 42:30 0.157 2.0 [1-3.8] 0.330 1.4 [0.7-2.6] 0.257 1.5 [0.7-3.3] 
5 rs726281  A 48:24 0.005d 2.1 [1.2-3.6] 0.041 2.2 [1.0-4.9] 0.024 2.3 [1.1-4.8] 
6 rs3020407  A 52:38 0.140 1.4 [0.9-2.1] 0.317 1.4 [0.7-2.7] 0.170 1.6 [0.8-3.2] 
7 rs17081994  T 20:11 0.106 1.8 [0.9-3.8] 0.090 2.4 [0.8-6.8] 0.564 1.4 [0.4-4.4] 
8 rs2982712  T 61:46 0.147 1.3 [0.9-1.9] 0.064 1.8 [1.0-3.4] 0.647 1.2 [0.6-2.1] 
9 rs3020371  C 53:41 0.216 1.3 [0.9-1.9] 0.150 1.6 [0.8-3.0] 0.622 1.2 [0.6-2.2] 
10 rs2228480  G 31:23 0.276 1.3 [0.8-2.3] 0.670 .8 [0.4-1.9] 0.050 2.3 [1.0-5.2] 
11 rs3798577  T 66:42 0.021 1.6 [1.1-2.3] 0.307 1.4 [0.8-2.4] 0.008 2.4 [1.2-4.7] 
12 rs2295193  G 68:40 0.007 1.7 [1.2-2.5] 0.123 1.6 [0.9-3.0] 0.004 2.6 [1.3-5.3] 
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13 rs2252837  C 57:43 0.162 1.3 [0.9-2.0] 0.182 1.6 [0.8-3.1] 0.355 1.3 [0.7-2.5] 
aOT: Over-transmitted allele. bT:U: Transmitted versus untransmitted allele. cOR [CI95]: odds ratio and the 95% confidence interval. dSignificant 
p values are indicated in bold. 
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Table 4: Transmission disequilibrium test of ESR1 SNPs with restrictive AN of German family-based cohort 
        Parental TDT  Maternal TDT  Paternal TDT 
SNP# Markers MAFa   OTb T:Uc p OR [CI95]d  T:U p OR [CI95]  T:U p OR [CI95] 
4 rs1884051 G (0.30)   G 20:15 0.398 1.3 [0.7-2.6]  09:09 1 1 [0.4-2.5]  11:06 0.225 1.8 [0.7-5.0] 
5 rs726281 G (0.27)   G 23:14 0.139 1.6 [0.8-3.2]  08:09 0.808 0.9 [0.3-2.3]  15:05 0.025e 3 [1.1-8.3] 
6 rs3020407 G (0.33)   A 17:16 0.862 1.1 [0.5-2.1]  11:06 0.225 1.8 [0.7-5.0]  06:10 0.317 0.6 [0.2-1.7] 
7 rs17081994 C (0.09)   C 08:05 0.405 1.6 [0.5-4.9]  01:02 0.564 0.5 [0-5.5]  06:02 0.157 3 [0.6-14.9] 
9 rs3020371 T (0.32)   T 22:16 0.330 1.4 [0.7-2.6]  09:08 0.808 1.1 [0.4-2.9]  12:07 0.251 1.7 [0.7-4.4] 
10 rs2228480 A (0.19)   G 15:13 0.705 1.2 [0.5-2.4]  08:06 0.593 1.3 [0.5-3.8]  08:07 0.796 1.1 [0.4-3.2] 
11 rs3798577 C (0.40)   T 23:13 0.096f 1.8 [0.9-3.5]  10:08 0.637 1.3 [0.5-3.2]  13:05 0.059 2.6 [0.9-7.3] 
12 rs2295193 A (0.45)   - 21:21 1 1 [0.5-1.8]  11:11 1 1 [0.4-2.3]  10:10 1 1 [0.4-2.4] 
aMAF: Minor allele and its frequency in the parentheses. bOT: Over-transmitted allele. cT:U: Transmitted versus untransmitted allele. dOR [CI95]: 
odds ratio and the 95% confidence interval. eSignificant p values are indicated in bold. fTrend of significance for p values are indicated in italic. 
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Table 5: Association of ESR1 rs3798577 tag-SNP with AN in a population-based sample of 693 French Caucasian women. 
    Genotype     
  CC  CT  TT  Total 
  N %  N %  N %  N % 
SCOFF<2  128 22.6  284 50.1  155 27.3  567 100 
SCOFF≥2  19 15.1  59 46.8  48 38.1  126 100 
p value (Additive model) = 0.008 
 

